Huatai Pharma
China Updated 9 July 2026
Huatai Pharma is an API manufacturer based in China. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 24 March 2023 as VAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| China, China | 3012212599 |
What they file, and where
Also appears on these molecule pages
Comparing suppliers?
Choose your molecules and target markets. Huatai Pharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 24 March 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability